Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
New Jersey’s THC beverage market is heading into the most consequential stretch of its short…
Mormon Wives star Mikayla Matthews says medical cannabis was “literally life-changing” for her nerve pain…
Chains reorder every two weeks and earn twice the discounts. Independents stock the same breadth…
We head to Canna Country Farms in Humboldt for Legendary Strains to discover the Ocimene…
Cannabis advocates should take the lesson here too. The industry doesn't need to inflate its…
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…